Appointment of the Company’s Supervisory Board for the next term of office

Current report no. 33/2026 

Date of preparation: 19 June 2026  

Subject: Appointment of the Company’s Supervisory Board for the next term of office 

Legal basis: Article 56(1)(2) of the Act on Offering - current and periodic information 

The Management Board of Captor Therapeutics S.A. (the “Company”) hereby announces that on 19 June 2026, the Annual General Meeting elected the following persons as members of the Company’s Supervisory Board for the next joint term of office of 3 (three) years: 

1. Mr Robert Florczykowski; 

2. Mr Andrew Galazka; 

3. Mr Paweł Holstinghausen Holsten; 

4. Mr Krzysztof Samotij; 

5. Mr Charles Kunsch; 

6. Mr Michał Wnorowski; 

7. Mr Maciej Wróblewski. 

The Company attaches the CVs of the above-mentioned persons, including a description of their previous positions and professional career history. 

All of the above-mentioned persons, in accordance with the declarations submitted, do not engage in any activity competitive to that carried out by the Company, nor do they hold an interest in a competing company as partners in a civil law partnership, a partnership or a company limited by shares, nor do they hold a position in a competing legal entity as members of its governing body. 

In accordance with the declarations submitted, the above-mentioned persons are not entered in the Register of Insolvent Debtors maintained pursuant to the Act on the National Court Register. 

Specific legal basis: 

Section 5(6) in conjunction with Section 11 of the Regulation of the Minister of Finance of 6 June 2025 on current and periodic information disclosed by issuers of securities and the conditions for recognising as equivalent information required by the laws of a non-Member State.